tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2014 Sep 10. pii: CVI.00572-14. [Epub ahead of print]
AAV9-mediated airway expression of antibody protects old and immunodeficient mice against influenza.
Adam VS1, Crosariol M1, Kumar S1, Ge MQ2, Czack SE1, Roy S1, Haczku A2, Tretiakova A1, Wilson JM1, Limberis MP3.
Author information
Abstract
Influenza causes serious and at times fatal disease in those at risk due to advanced age or immunodeficiencies. Despite progress in the development of seasonal influenza vaccines, vaccine efficacy in the elderly and immunocompromised remains low. We recently developed a passive immunization strategy using an adeno-associated virus (AAV) vector to deliver a neutralizing anti-influenza antibody at the site of infection; the nasal airways. Here we show that young, old and immunodeficient (SCID) mice that were treated i.n. with AAV9 vector expressing a modified version of the broadly neutralizing anti-influenza antibody, FI6, were protected and exhibited no signs of disease following an intranasal challenge with the mouse-adapted H1N1 influenza strain A/Puerto Rico/8/1934 H1N1 (PR8). Non-vaccinated mice succumbed to the PR8 challenge due to severe weight loss. We propose that airway-directed AAV9 passive immunization against airborne infectious agents may be beneficial in the elderly and in immunocompromised patients for which there still exists an unmet need for effective vaccination against influenza.
Copyright ? 2014, American Society for Microbiology. All Rights Reserved.
PMID:
25209558
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25209558
AAV9-mediated airway expression of antibody protects old and immunodeficient mice against influenza.
Adam VS1, Crosariol M1, Kumar S1, Ge MQ2, Czack SE1, Roy S1, Haczku A2, Tretiakova A1, Wilson JM1, Limberis MP3.
Author information
Abstract
Influenza causes serious and at times fatal disease in those at risk due to advanced age or immunodeficiencies. Despite progress in the development of seasonal influenza vaccines, vaccine efficacy in the elderly and immunocompromised remains low. We recently developed a passive immunization strategy using an adeno-associated virus (AAV) vector to deliver a neutralizing anti-influenza antibody at the site of infection; the nasal airways. Here we show that young, old and immunodeficient (SCID) mice that were treated i.n. with AAV9 vector expressing a modified version of the broadly neutralizing anti-influenza antibody, FI6, were protected and exhibited no signs of disease following an intranasal challenge with the mouse-adapted H1N1 influenza strain A/Puerto Rico/8/1934 H1N1 (PR8). Non-vaccinated mice succumbed to the PR8 challenge due to severe weight loss. We propose that airway-directed AAV9 passive immunization against airborne infectious agents may be beneficial in the elderly and in immunocompromised patients for which there still exists an unmet need for effective vaccination against influenza.
Copyright ? 2014, American Society for Microbiology. All Rights Reserved.
PMID:
25209558
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25209558